» Articles » PMID: 30061587

Practice-changing Radiation Therapy Trials for the Treatment of Cancer: Where Are We 150 Years After the Birth of Marie Curie?

Overview
Journal Br J Cancer
Specialty Oncology
Date 2018 Aug 1
PMID 30061587
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

As we mark 150 years since the birth of Marie Curie, we reflect on the global advances made in radiation oncology and the current status of radiation therapy (RT) research. Large-scale international RT clinical trials have been fundamental in driving evidence-based change and have served to improve cancer management and to reduce side effects. Radiation therapy trials have also improved practice by increasing quality assurance and consistency in treatment protocols across multiple centres. This review summarises some of the key RT practice-changing clinical trials over the last two decades, in four common cancer sites for which RT is a crucial component of curative treatment: breast, lung, urological and lower gastro-intestinal cancer. We highlight the global inequality in access to RT, and the work of international organisations, such as the International Atomic Energy Agency (IAEA), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the United Kingdom National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad), that aim to improve access to RT and facilitate radiation research. We discuss some emerging RT technologies including proton beam therapy and magnetic resonance linear accelerators and predict likely future directions in clinical RT research.

Citing Articles

German radiation oncology's next generation: a web-based survey of young biologists, medical physicists, and physicians-from problems to solutions.

Weissmann T, Deloch L, Grohmann M, Trommer M, Fabian A, Ehret F Strahlenther Onkol. 2024; 200(12):1005-1024.

PMID: 39436419 PMC: 11588816. DOI: 10.1007/s00066-024-02305-8.


Herbal Medicine-Derived Exosome-Like Nanovesicles: A Rising Star in Cancer Therapy.

Chu K, Liu J, Zhang X, Wang M, Yu W, Chen Y Int J Nanomedicine. 2024; 19:7585-7603.

PMID: 39081899 PMC: 11287466. DOI: 10.2147/IJN.S477270.


Building bridges between clinic and community: Supporting patients and caregivers living in rural and remote Canada.

Booker R Can Oncol Nurs J. 2024; 33(4):509-516.

PMID: 38919591 PMC: 11195820.


An Innovative Inducer of Platelet Production, Isochlorogenic Acid A, Is Uncovered through the Application of Deep Neural Networks.

Yi T, Luo J, Liao R, Wang L, Wu A, Li Y Biomolecules. 2024; 14(3).

PMID: 38540688 PMC: 10968240. DOI: 10.3390/biom14030267.


Insights into the radiotherapy-induced deferentially expressed RNAs in colorectal cancer management.

Karimpur Zahmatkesh A, Moqadami A, Khalaj-Kondori M Iran J Basic Med Sci. 2023; 26(12):1380-1389.

PMID: 37970448 PMC: 10634048. DOI: 10.22038/IJBMS.2023.71259.15482.


References
1.
Lange M, Maas C, Marijnen C, Wiggers T, Rutten H, Kranenbarg E . Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg. 2008; 95(8):1020-8. DOI: 10.1002/bjs.6126. View

2.
Venables K, Miles E, Aird E, Hoskin P . The use of in vivo thermoluminescent dosimeters in the quality assurance programme for the START breast fractionation trial. Radiother Oncol. 2004; 71(3):303-10. DOI: 10.1016/j.radonc.2004.02.008. View

3.
Kang J, Demaria S, Formenti S . Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016; 4:51. PMC: 5028964. DOI: 10.1186/s40425-016-0156-7. View

4.
Ahmad S, Duke S, Jena R, Williams M, Burnet N . Advances in radiotherapy. BMJ. 2012; 345:e7765. DOI: 10.1136/bmj.e7765. View

5.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A . Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2017; 36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. View